Patrick Ronaldson
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Patrick Ronaldson is a Professor at The University of Arizona, United States. His research focuses on the mechanisms of drug delivery and neuroprotection in the context of stroke, as evidenced by his recent publications on blood-brain barrier transporters and their implications for therapeutic development. His work aims to bridge the gap between laboratory research and clinical application, particularly regarding the treatment of ischemic stroke.
Recent Grants
Grant: Close
Statins Require Endogenous Blood-Brain Barrier Transporters to Confer Neuroprotective Effects in Stroke.
Open Date: 2019-07-01
Close Date: 2022-06-30
Grant: Close
Targeting blood-brain barrier transporters to treat hypoxia/reoxygenation stress
Open Date: 2014-07-01
Close Date: 2019-06-30
Articles (5)
Drug development for ischemic stroke is challenging as evidenced by the paucity of therapeutics that have advanced beyond a phase III trial. There are many reasons for this lack of clinical translation including factors related to the experimental design of preclinical studies. Often overlooked in therapeutic development for ischemic stroke is the requirement of effective drug delivery to the brain, which is critical for neuroprotective efficacy of several small and large molecule drugs. Advancing central nervous system drug delivery technologies implies a need for detailed comprehension of the blood-brain barrier (BBB) and neurovascular unit. Such knowledge will permit the innate biology of the BBB/neurovascular unit to be leveraged for improved bench-to-bedside translation of novel stroke therapeutics. In this review, we will highlight key aspects of BBB/neurovascular unit pathophysiology and describe state-of-the-art approaches for optimization of central nervous system drug delivery (ie, passive diffusion, mechanical opening of the BBB, liposomes/nanoparticles, transcytosis, intranasal drug administration). Additionally, we will discuss how endogenous BBB transporters represent the next frontier of drug delivery strategies for stroke. Overall, this review will provide cutting edge perspective on how central nervous system drug delivery must be considered for the advancement of new stroke drugs toward human trials.
Year:
2024
Year:
2023
Year:
2022
Year:
2022
Year:
2020
Collaborators (1)
Thomas P. Davis
University of Arizona
Make your next move.
Prepare your application
Review drafts before you send them.